key: cord-0968894-b8z79e0c
authors: de Souza, Anacleto Silva; de Freitas Amorim, Vitor Martins; Guardia, Gabriela D A; dos Santos, Felipe R C; dos Santos, Filipe F; de Souza, Robson Francisco; de Araujo Juvenal, Guilherme; Huang, Yihua; Ge, Pingju; Jiang, Yinan; Paudel, Prajwal; Ulrich, Henning; Galante, Pedro A F; Guzzo, Cristiane Rodrigues
title: Molecular dynamics analysis of fast-spreading severe acute respiratory syndrome coronavirus 2 variants and their effects in the interaction with human angiotensin-converting enzyme 2
date: 2021-06-15
journal: bioRxiv
DOI: 10.1101/2021.06.14.448436
sha: 861e96e349030988f777342bc687ff9f8fcec5bd
doc_id: 968894
cord_uid: b8z79e0c

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is evolving with mutations in the Spike protein, especially in the receptor-binding domain (RBD). The failure of public health measures to contain the spread of the disease in many countries has given rise to novel viral variants with increased transmissibility. However, key questions about how quickly the variants can spread and whether they can cause a more severe disease remain unclear. Herein, we performed a structural investigation using molecular dynamics simulations and determined dissociation constant (KD) values using surface plasmon resonance (SPR) assays of three fastspreading SARS-CoV-2 variants, Alpha, Beta and Gamma ones, as well as genetic factors in the host cells that may be related to the viral infection. Our results suggest that the SARS-CoV-2 variants facilitate their entry into the host cell by moderately increased binding affinities to the human ACE2 receptor, different torsions in hACE2 mediated by RBD variants, and an increased Spike exposure time to proteolytic enzymes. We also found that other host cell aspects, such as gene and isoform expression of key genes for the infection (ACE2, FURIN and TMPRSS2), may have few contributions to the SARS-CoV-2 variants infectivity. In summary, we concluded that a combination of viral and host cell factors allows SARS-CoV-2 variants to increase their abilities to spread faster than wild-type.

We are facing an unprecedented pandemic situation caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) 1,2 , responsible for the death of more than 3,718,683 people and infected more than 170 millions worldwide, as on June 06 th , 2021 3 . The first outbreak of SARS-CoV-2 was reported in December 2019 at Wuhan, China, causing a severe respiratory syndrome known as Coronavirus Disease 2019 (COVID- 19) 3 . The virus surface glycoprotein Spike (S) is composed of two subunits, S1 and S2. S1 has the receptor-binding domain (RBD) that interacts with the human angiotensin-converting enzyme 2 (hACE2) 4 , while S2 mediates viral and host cellular membrane fusions 5, 6 . The process of virus invasion only occurs after cleavage of two proteolytic sites in the S protein, S1/S2, processed by a furinlike protein convertase (FURIN), and S2', processed by a transmembrane protease surface serine 2 (TMPRSS2) [7] [8] [9] [10] . A third protease also enhances virus entry, the lysosomal cysteine protease cathepsin L (CTSL) 10 . These proteolytic processes cleave the S1 subunit and induce drastic conformational changes in the S2 subunit allowing the membrane fusion and release of virus genetic information inside the host cell.

Actually, the world has already gone through two waves, and a third one is imminent with the emergence of novel SARS-CoV-2 variants. According to the World Health Organization (WHO) criteria, a variant of concern (VOC) is defined mainly due to its increased transmissibility, higher virulence or altered clinical characteristics of the disease 11 . The first VOC reported was in the United Kingdom, also called B.1.1.7 (Alpha variant; Sept 2020), which quickly became prevalent in the British population 12 October 2020) 13 . It is evident that these variants have already affected the trajectory of the pandemic in countries where they originated. The SARS-CoV-2 population seems to be still adapting to its human host, since an accumulation of multiple mutations in the S protein are being observed in new variants (Figure 1a) . Some virus variants have been reported to increase transmissibility, lethality, and to be associated with decreased effectiveness of neutralizing antibodies (Tables S1 and S2) 14, 15 . However, key questions remain about how quickly the variants can spread, their potential to evade immunity and whether they can cause a more severe disease. In order to shed light on these key questions, we performed computational and experimental assays to investigate the changes in binding affinity of three fastspreading SARS-CoV-2 variants, the Alpha, Beta and Gamma ones, and their cellular entrance, the hACE2. We thus discuss the possible implications of our molecular interaction results to the higher spread and infectivity of the variants.

In order to evaluate the potential impact of fast-spreading variants B.1.1.7 (RBD B.1.1.7 ), B.1.351 (RBD B.1.351 ), and P.1 (RBD P.1 ) in the interaction with hACE2, we performed molecular dynamics (MD) simulations for 100 ns using RBD (residues 333-526) and hACE2 (residues 19-615) (Figure 2) . SARS-CoV-2 RDB binds to hACE2 through two different regions, the E1 (residues 417, 455-456, and 470-490) and E2 (444-454 and 493-505) (Figure 1b) 16 (Figures 2 and S2) . Consistent with our previous study 16 Table S3 ).

Additionally, RBD P.1 and RBD B.1.351 have an E484K mutation, causing a chargerepelling impact with K31 hACE2 . These variants also present the mutations K417T and K417N, respectively. The K417 and E484 mutations seem to reverse the effect of the N501Y mutation in the loop of residues 474-488, restoring a more original conformational state (Figures 2c-g and S2a-b) .

We also calculated the covariance matrix of the spatial displacements of C α atoms to study internal motions of the hACE2/RBD WT complex and compared them with different SARS-CoV-2 RBD mutants (Figures 3 and S5 ; Tables S4 and S5).

The sets of intermolecular and intramolecular covariant pairs changed between different SARS-CoV-2 RBD mutants and RBD WT ( (Figure 3) . We also calculated the principal components using MD trajectories to provide the main structural insights of the RBD/hACE2 complexes from eigenvalues and orthogonal eigenvectors (Figures 4 and S6) . These orthogonal eigenvectors are associated with the maximum covariance between residue pairs. Thus, we observed 100 snapshots corresponding to MD trajectories obtained by the first eigenvalue of the RBD WT /hACE2 and RBD variants /hACE2 complexes (Figure 4) . The movement of the RBD and hACE are different in each analyzed complex, demonstrating that RBD induces different torsions in the hACE2 (Figure 4 and supplementary movies S1

and S2). In this regard, we hypothesized that observed torsions in hACE2 may be (Table S8 ) [20] [21] [22] [23] [24] . Although there are only slight differences in the K D values, significant differences in k a and k d rates point to altered binding kinetics (Table 1 and S7) . We investigated whether expression profiles of three essential genes for the viral entrance into the human cells, ACE2, TMPRSS2, and FURIN may be determinative for infection rates. We analyzed approximately 23,000 samples (~1,000 individuals) from 32 healthy tissues and, to gain more insight about their expression patterns, we also sectioned them in gender, donors' age (young < 40; old > 60 years old) and ACE2 splicing isoforms (Figure 5 ). ACE2 has a high or middle expression in organs of respiratory tract (lung), cardiovascular (heart), digestive (colon and small intestine), endocrine (testis, thyroid), adipose tissue, breast and kidney (Figure 5a) . TMPRSS2 has a similar expression pattern. Notably, both genes are low expressed in the nervous system (Figure 5a and Figure S10) . Conversely, FURIN is highly expressed in almost all human tissues ( Figure S11 ). Figure 5b summarizes organs presenting high expression of ACE2 and TMPRSS2 or FURIN (red marked). Most of them are already known to be critical organs for the disease (e.g., lung and heart). Interestingly, a new ACE2 splicing isoform was recently reported 35,36 , 35,36 which lacks the S1 RBD interaction region, is induced by interferons but has no metallopeptidase activity. Then, we investigated the expression of this isoform (dACE2), as well as the full-lenght (fACE2) and other ACE2 alternative isoforms (pACE2) (Figure S12) . Figure 5c shows that the fulllength isoform, which contains receptor regions that interact with S RBD, is majorly expressed in all human tissues. Next, we also investigated the expression of these three genes by gender and age (young < 40; old > 60 years old). We did not find significant differential expression by age or gender for ACE2 (Figure 5d) , TMPRSS2

( Figure S13 ) or FURIN ( Figure S14) . Finally, we found a high expression correlation between ACE2 and the proteases, FURIN and TMPRSS2, suggesting a functional synergy in organs usually affected by the SARS-CoV-2 (Figure 5e ). In summary, we confirmed that ACE2 and either proteases, FURIN or TMPRSS2, are co-expressed in organs already described as affected by SARS-CoV-2, such as the respiratory, cardiovascular, digestive, and some endocrine organs. Using these expression data (Materials and Methods, in supporting information), no significant expression differences were found for these genes in terms of gender, age and ACE2 splicing isoforms.

Overall, our computational and experimental data show that the SARS-CoV-2 variants moderately increase their binding affinities to hACE2, which is not enough to 

The authors declare no conflict of interest. . ACE2 is expressed in critical tissues for the disease, its splicing isoforms are less expressed than its full-length sequence, and there is no significant expression difference between gender or age for this gene. a) ACE2 gene expression profile in 32 human healthy tissues. b) Schematic representation of organs showing higher expression of ACE2 and TMPRSS2 or FURIN genes. c) Expression profile of ACE2 splicing isoforms. d) ACE2 expression profile segmented by age (young < 40; old > 60 years old) and gender. e) Expression correlation (Rho = spearman coefficient) between ACE2 and FURIN or ACE2 and TMPRSS2. 

The Proximal Origin of SARS-CoV-2

SARS-CoV-2 Jumping the Species Barrier: Zoonotic Lessons from SARS, MERS and Recent Advances to Combat This Pandemic Virus

Structure of the SARS-CoV-2 Spike Receptor-Binding Domain Bound to the ACE2 Receptor

Insights from the Association of SARS-CoV S-Protein with Its Receptor, ACE2

An Overview of Their Replication and Pathogenesis

Evidence That TMPRSS2 Activates the Severe Acute Respiratory Syndrome Coronavirus Spike Protein for Membrane Fusion and Reduces Viral Control by the Humoral Immune Response

Inhibitors of Cathepsin L Prevent Severe Acute Respiratory Syndrome Coronavirus Entry

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

Cathepsin L Plays a Key Role in SARS-CoV-2 Infection in Humans and Humanized Mice and Is a Promising Target for New Drug Development

Proposed working definitions of SARS-CoV-2 Variants of Interest and Variants of Concern

PHE. Investigation of novel SARS-COV-2 variant

Vaccine-Elicited Antibodies to SARS-CoV-2 and Circulating Variants

Escapes Neutralization by South African COVID-19 Donor Plasma

Molecular Dynamics Reveals Complex Compensatory Effects of Ionic Strength on the Severe Acute Respiratory Syndrome Coronavirus 2 Spike/Human Angiotensin-Converting Enzyme 2 Interaction

Simple Method for Displaying the Hydropathic Character of a

Cryo-Electron Microscopy Structures of the N501Y SARS-CoV-2 Spike Protein in Complex with ACE2 and 2 Potent Neutralizing Antibodies

Distinct Conformational States of SARS-CoV-2 Spike Protein

SARS-CoV-2 B.1.1.7 and B.1.351 Spike Variants Bind Human ACE2 with Increased Affinity

CITIID-NIHR BioResource COVID-19 Collaboration

Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA Vaccine-Elicited Antibodies

Mutation N501Y in RBD of Spike Protein Strengthens the Interaction between COVID-19 and Its Receptor ACE2. bioRxiv

Experimental Evidence for Enhanced Receptor Binding by Rapidly Spreading SARS-CoV-2 Variants. bioRxiv

Structural Basis for Enhanced Infectivity and Immune Evasion of SARS-CoV-2 Variants

Receptor Binding and Priming of the Spike Protein of SARS-CoV-2 for Membrane Fusion

The Discovery of a Putative Allosteric Site in the SARS-CoV-2 Spike Protein Using an Integrated Structural/Dynamic Approach

Leaving No Stone Unturned: Allosteric Targeting of SARS-CoV-2 Spike Protein at Putative Druggable Sites Disrupts Human Angiotensin-Converting Enzyme Interactions at the Receptor Binding Domain

Heparin Inhibits Cellular Invasion by SARS-CoV-2: Structural Dependence of the Interaction of the Spike S1 Receptor-Binding Domain with Heparin

Heparan Sulfate Assists SARS-CoV-2 in Cell Entry and Can Be Targeted by Approved Drugs in Vitro

Higher Binding Affinity of Furin for SARS-CoV-2 Spike (S) Protein D614G Mutant Could Be Associated with Higher SARS-CoV-2 Infectivity

Structural Impact on SARS-CoV-2 Spike Protein by D614G Substitution

Effect of Natural Mutations of SARS-CoV-2 on Spike Structure, Conformation and Antigenicity. bioRxiv 2021

Evidence of Escape of SARS-CoV-2 Variant B.1.351 from Natural and Vaccine-Induced Sera

A Novel ACE2 Isoform Is Expressed in Human Respiratory Epithelia and Is Upregulated in Response to Interferons and RNA Respiratory Virus Infection

Prokunina-Olsson, L. Interferons and Viruses Induce a Novel Truncated ACE2 Isoform and Not the Full-Length SARS-CoV-2 Receptor

Spike Mutation D614G Alters SARS-CoV-2 Fitness

SARS-CoV-2 D614G Spike Mutation Increases Entry Efficiency with Enhanced ACE2-Binding Affinity

SARS-CoV-2 Spike-Protein D614G Mutation Increases Virion Spike Density and Infectivity